Class / Patent application number | Description | Number of patent applications / Date published |
514578000 | Acyclic acid or salt thereof | 19 |
20080214671 | Dicarbonic Acid Derivatives, Metastasis Inhibitors and Agents Increasing Chemotherapeutic Activity of Anti-Tumor Preparations, Method for Enhancing the Cytostatic Efficiency and Metastasis Process Inhibiting Method - The invention relates to dicarbonic acid derivatives and concerns dicarbonic acid monooxydamines and dioxydamides, which are physiologically active substances and can be used as low-toxic and non-toxic agents for enhancing the anti-tumor and anti-metastasis effects of known cytostatics (cyclophosphane and cisplatin) in cytostatic chemotherapy of tumors. | 09-04-2008 |
20080234382 | METHODS FOR THE PREPARATION, FORMULATION AND USE OF LITHIUM VALPROATE - The present invention relates to methods for preparing lithium valproate and administering this compound to a subject in need of treatment with lithium and/or valproate. Pharmaceutical compositions are also provided that are useful therapies for the treatment of neurological, immunological, and viral-mediated disorders in warm-blooded mammals. | 09-25-2008 |
20080269338 | AQUEOUS SOLUTIONS CONTAINING CHLORAMINE WHICH ARE FREE FROM DI-AND TRICHLOROAMINE, AS WELL AS FROM AMMONIA - The combination of N-chlorotaurine, preferably in the form of sodium salt, and ammonium chloride in aqueous solution absent a buffer is a powerful antiseptic preparation sufficiently stable for use in topical treatment of infections, inflammation and oozing tissue deficiencies. The outstanding microbicidal properties of the preparation are founded in the formation of monochloramine, which is distinguished by the absence, or substantial absence, of dichloramine and trichloramine. | 10-30-2008 |
20080269339 | COMBINED USE OF EGF PATHWAY INHIBITORS AND DIFFERENTIATION PROMOTING COMPOUNDS - The present invention is a pharmaceutical composition and method for its use in the treatment of chronic inflammatory skin diseases such as psoriasis. The pharmaceutical composition combines an inhibitor of the EGF receptor signaling pathway with an agent that promotes cell differentiation. This pharmaceutical results in superior treatment of chronic inflammatory skin diseases than methods presently in use. | 10-30-2008 |
20080275126 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 11-06-2008 |
20090023812 | N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES - The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds. | 01-22-2009 |
20090082455 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE - An agent for the prevention, treatment and/or inhibition of progression of an ophthalmic disease and an agent for the protection of an optic nerve, each of which comprises (2R)-2-propyloctanoic acid or a salt or prodrug thereof in which an amount per dose is from 0.3 ng to 5000 mg. The agents are useful for an ophthalmic disease, such as glaucoma, cataract, retinal detachment, muscae volitantes, age-related macular degeneration, diabetic retinopathy, macular edema, myopia, asthenopia, dry eye, amaurosis fugax, choked disc, papillitis optica, retrobulbar neuritis, toxic amblyopia, optic atrophy, higher visual pathway lesion, internuclear opthalmoplegia, gaze palsy and ischemic optic neuropathy. | 03-26-2009 |
20100210730 | N-HALOGENATED AMINO ACID FORMULATIONS WITH ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification further describes a method for treating respiratory infections comprising contacting the site of the respiratory infection with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. | 08-19-2010 |
20110152375 | METHOD OF REDUCING THE METHANE GAS LEVEL AND OF INCREASING THE TOTAL GAS YIELD IN ANIMAL FEED - The present invention relates to the use of at least one porous metal-organic framework material (MOF) comprising at least one first and, if appropriate, one second organic compound, where at least the first organic compound binds coordinatively to at least one metal ion in an at least partly bidentate manner, where the at least one metal ion is Mg(II) and where the first organic compound is derived from formic acid and the second organic compound from acetic acid, for reducing the methane level in the total gas produced, and to the use for increasing the total gas formation during feed digestion in ruminants as well as a method for reducing the methane level in the total gas produced and a method for increasing the total gas formation during feed digestion in ruminants. | 06-23-2011 |
20110196041 | Novel crystal form of calcium 3-acetylaminopropane-1-sulfonate - The present invention relates to a novel crystal form of calcium 3-acetylaminopropane-1-sulfonate, to a process for the preparation thereof, and to the use thereof in medicaments. | 08-11-2011 |
20110281951 | Compositions and methods for treating amyloidosis - Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula | 11-17-2011 |
20120077878 | GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT - Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described. | 03-29-2012 |
20120202883 | EFFECTS OF IDH1 AND IDH2 MUTATIONS ON THE CELLULAR METABOLOME - Point mutations of the NADP | 08-09-2012 |
20130085182 | SODIUM 2-MERCAPTOETHANE SULFONATE FOR USE IN THE TREATMENT OF LUMBAR PAIN - The present invention refers to 2-mercaptoethane sulfonate or pharmaceutically acceptable salts thereof and to pharmaceutical compositions comprising it for epidural use in the treatment of lumbar pain. | 04-04-2013 |
20130137772 | HYDROXYPOLYAMINE SALTS - A salt of a polyamine having the formula: | 05-30-2013 |
20130165521 | TREATMENT OF FUNGAL INFECTIONS - The present disclosure relates to compositions comprising formic acid as an active ingredient and a softening agent or emollient for use in the treatment of fungal infections of the skin and/or nail(s) of mammals, as well as methods for treatment utilizing such compositions. | 06-27-2013 |
20130296434 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS - Methods, formulations, and compositions for the treatment of amyloidosis are described. | 11-07-2013 |
20140350113 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF - Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556. | 11-27-2014 |
20160184224 | GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT - Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described. | 06-30-2016 |